Korro Bio’s Promising Regulatory and Preclinical Advances Earn a Buy Rating from Analyst Mitchell Kapoor
H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating on Korro Bio (KRRO – Research Report) today and set a price target of ...
Korro Bio (KRRO) Gets a Buy from Piper Sandler
Piper Sandler analyst Yasmeen Rahimi maintained a Buy rating on Korro Bio (KRRO – Research Report) today and set a price target of ...
Korro Announces Regulatory Filing for Initiation of KRRO-110 First-In-Human Study and Formation of Clinical Advisory Board
Antitrypsin Deficiency (AATD) submitted to Australian Bellberry Human Research Ethics Committee (HREC) -Clinical Advisory Board of lung and liver experts formed to support development of KRRO-110 ...
Investing2d
4 Biotech Stocks With AI, Machine Learning Prowess
Korro Bio (NASDAQ:KRRO) aims to "discover, develop and commercialize a new class of RNA therapies informed by human genetics ...
Lexaria Updates Fast-Moving GLP-1 'Arm's Race' Developments
Lexaria's strategy is to continue developing and optimizing our wholly-owned DehydraTECHâ„¢ drug delivery platform for application in the GLP-1 space, positioning it as a 'must-have' technology for ...
RNA editing promises to go where DNA editing can’t
The first two and some forms of obesity are associated with single-point mutations. Some other companies using ADAR enzymes ...
BioWorld5d
Korro Bio files in Australia to begin first-in-human study of KRRO-110 for AATD
Korro Bio Inc. has announced a submission to the Australian Bellberry Human Research Ethics Committee (HREC) for a phase I/II study of KRRO-110 for α-1 antitrypsin deficiency (AATD).
Benzinga.com4d
Gene Therapy Developer Beam Therapeutics Reports One Patient Death In Early-Stage Sickle Cell Disease Trial
Also Read: Gene Editing Korro Bio’s Preclinical Data ‘Best-In-Class’, Analyst Initiates With Outperform Rating In a company presentation, preliminary safety data (N=6) showed an initial ...